Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Michael Spiotto

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentRadiation & Cellular Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Michael Spiotto, MD, PhD, specializes in treating patients with head and neck cancer. Whenever possible, he uses image-guided radiation therapy to target a tumor more precisely while reducing damage to surrounding tissue.

    Dr. Spiotto currently serves as the primary investigator on a study examining the role of non-genotoxic inhibitors (agents that slow chemical reactions without damaging genetic tissue) in the spread of head and neck cancers caused by human papillomavirus (HPV). By studying the origin of HPV-induced cancers and understanding how they metastasize, he hopes to develop new treatment protocols and prevent relapse.

    An accomplished author, Dr. Spiotto's work has been published in scientific journals such as the Proceedings of the National Academy of Sciences, Immunity, Nature Medicine and Cancer Research. In addition, he has been a the recipient of several notable awards, including: the American Board of Radiology Holman Pathway, given to a trainee with exceptional clinical and research abilities; the University of Chicago's Leon O. Jacobson Basic Science Prize; and the John Van Prohaska Award for outstanding potential in teaching, research and clinical medicine.


    Collapse Biography 
    Collapse education and training
    University of Chicago, Chicago, ILPh.D.06/2003Pathology
    University of Chicago, Chicago, ILM.D.06/2005Medicine
    Memorial Sloan Kettering Cancer Center, New York, NY06/2006Internship
    Stanford University, Stanford, CA06/2010Residency

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ricco N, Flor A, Wolfgeher D, Efimova EV, Ramamurthy A, Appelbe OK, Brinkman J, Truman AW, Spiotto MT, Kron SJ. Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer. Mol Oncol. 2019 Jun 21. PMID: 31225926.
      View in: PubMed
    2. Foster CC, Rusthoven CG, Sher DJ, Feldman L, Pasquinelli M, Spiotto MT, Koshy M. Corrigendum to "Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall survival: A National Cancer Database Analysis" [Lung Cancer, Volume 130 (April) (2019) 162-168]. Lung Cancer. 2019 Jun; 132:159. PMID: 31031052.
      View in: PubMed
    3. Foster CC, Rusthoven CG, Sher DJ, Feldman L, Pasquinelli M, Spiotto MT, Koshy M. Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis. Lung Cancer. 2019 Apr; 130:162-168. PMID: 30885339.
      View in: PubMed
    4. Foster CC, Sher DJ, Rusthoven CG, Verma V, Spiotto MT, Weichselbaum RR, Koshy M. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis. Radiat Oncol. 2019 Jan 28; 14(1):18. PMID: 30691492.
      View in: PubMed
    5. Huang L, David O, Cabay RJ, Valyi-Nagy K, Macias V, Zhong R, Wenig B, Feldman L, Weichselbaum R, Spiotto MT. Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer. Clin Cancer Res. 2019 Mar 15; 25(6):1795-1808. PMID: 30573692.
      View in: PubMed
    6. Lu K, He C, Guo N, Chan C, Ni K, Lan G, Tang H, Pelizzari C, Fu YX, Spiotto MT, Weichselbaum RR, Lin W. Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy. Nat Biomed Eng. 2018 Aug; 2(8):600-610. PMID: 31015630.
      View in: PubMed
    7. Spiotto MT, Jefferson GD, Wenig B, Markiewicz MR, Weichselbaum RR, Koshy M. Survival outcomes for postoperative chemoradiation in intermediate-risk oral tongue cancers. Head Neck. 2017 12; 39(12):2537-2548. PMID: 28960621.
      View in: PubMed
    8. Koshy M, Sher DJ, Spiotto M, Husain Z, Engelhard H, Slavin K, Nicholas MK, Weichselbaum RR, Rusthoven C. Association between hospital volume and receipt of treatment and survival in patients with glioblastoma. J Neurooncol. 2017 Dec; 135(3):529-534. PMID: 28836140.
      View in: PubMed
    9. Spiotto MT, Jefferson G, Wenig B, Markiewicz M, Weichselbaum RR, Koshy M. Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer: A National Cancer Database Analysis. JAMA Otolaryngol Head Neck Surg. 2017 07 01; 143(7):691-699. PMID: 28426848.
      View in: PubMed
    10. Koshy M, Malik R, Spiotto M, Mahmood U, Rusthoven CG, Sher DJ. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy. Lung Cancer. 2017 06; 108:222-227. PMID: 28625640.
      View in: PubMed
    11. Spiotto MT, Koshy M. Impact of fraction size on locally advanced oropharyngeal and nasopharyngeal cancers treated with chemoradiation. Oral Oncol. 2017 05; 68:27-35. PMID: 28438289.
      View in: PubMed
    12. Melotek JM, Cooper BT, Koshy M, Silverman JS, Spiotto MT. Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer. J Otolaryngol Head Neck Surg. 2016 Nov 24; 45(1):62. PMID: 27881143.
      View in: PubMed
    13. Spiotto M, Fu YX, Weichselbaum RR. The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. Sci Immunol. 2016 Sep; 1(3). PMID: 28018989.
      View in: PubMed
    14. Spiotto MT. Return of induction chemotherapy in head and neck squamous cell cancers: is this time different? Lancet Oncol. 2016 11; 17(11):1465-1467. PMID: 27686944.
      View in: PubMed
    15. Zheng W, Skowron KB, Namm JP, Burnette B, Fernandez C, Arina A, Liang H, Spiotto MT, Posner MC, Fu YX, Weichselbaum RR. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget. 2016 Jul 12; 7(28):43039-43051. PMID: 27343548.
      View in: PubMed
    16. Bechill J, Zhong R, Zhang C, Solomaha E, Spiotto MT. A High-Throughput Cell-Based Screen Identified a 2-[(E)-2-Phenylvinyl]-8-Quinolinol Core Structure That Activates p53. PLoS One. 2016; 11(4):e0154125. PMID: 27124407.
      View in: PubMed
    17. Villaflor VM, Melotek JM, Karrison TG, Brisson RJ, Blair EA, Portugal L, De Souza JA, Ginat DT, Stenson KM, Langerman A, Kocherginsky M, Spiotto MT, Hannigan N, Seiwert TY, Cohen EE, Vokes EE, Haraf DJ. Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13. PMID: 26884588.
      View in: PubMed
    18. Spiotto MT, Connell PP. Strategies to Overcome Late Complications from Radiotherapy for Childhood Head and Neck Cancers. Oral Maxillofac Surg Clin North Am. 2016 Feb; 28(1):115-26. PMID: 26614704.
      View in: PubMed
    19. Zhong R, Bechill J, Spiotto MT. Loss of E2F1 Extends Survival and Accelerates Oral Tumor Growth in HPV-Positive Mice. Cancers (Basel). 2015 Dec 08; 7(4):2372-85. PMID: 26670255.
      View in: PubMed
    20. Spiotto MT, Koshy M. Hospitalizations of more than 5 days predict for worse outcomes after radiotherapy for head and neck cancer. J Community Support Oncol. 2015 Oct; 13(10):367-73. PMID: 26862912.
      View in: PubMed
    21. Jefferson GD, Wenig BL, Spiotto MT. Predictors and outcomes for chronic tracheostomy after chemoradiation for advanced laryngohypopharyngeal cancer. Laryngoscope. 2016 Feb; 126(2):385-91. PMID: 26344401.
      View in: PubMed
    22. Zhong R, Bao R, Faber PW, Bindokas VP, Bechill J, Lingen MW, Spiotto MT. Notch1 Activation or Loss Promotes HPV-Induced Oral Tumorigenesis. Cancer Res. 2015 Sep 15; 75(18):3958-3969. PMID: 26294213.
      View in: PubMed
    23. Spiotto MT, Cao H, Mell L, Toback FG. Angiotensin-converting enzyme inhibitors predict acute kidney injury during chemoradiation for head and neck cancer. Anticancer Drugs. 2015 Mar; 26(3):343-9. PMID: 25486599.
      View in: PubMed
    24. Koshy M, Malik R, Sher DJ, Spiotto M, Mahmood U, Aydogan B, Weichselbaum RR. The effect of radiotherapy dose on survival in stage III non-small-cell lung cancer patients undergoing definitive chemoradiotherapy. Clin Lung Cancer. 2014 Sep; 15(5):365-71. PMID: 24984565.
      View in: PubMed
    25. Spiotto MT, Weichselbaum RR. Comparison of 3D confromal radiotherapy and intensity modulated radiotherapy with or without simultaneous integrated boost during concurrent chemoradiation for locally advanced head and neck cancers. PLoS One. 2014; 9(4):e94456. PMID: 24714187.
      View in: PubMed
    26. Zhong R, Pytynia M, Pelizzari C, Spiotto M. Bioluminescent imaging of HPV-positive oral tumor growth and its response to image-guided radiotherapy. Cancer Res. 2014 Apr 01; 74(7):2073-81. PMID: 24525739.
      View in: PubMed
    27. Ranck MC, Abundo R, Jefferson G, Kolokythas A, Wenig BL, Weichselbaum RR, Spiotto MT. Effect of postradiotherapy neck dissection on nonregional disease sites. JAMA Otolaryngol Head Neck Surg. 2014 Jan; 140(1):12-21. PMID: 24263403.
      View in: PubMed
    28. Zakeri K, MacEwan I, Vazirnia A, Cohen EE, Spiotto MT, Haraf DJ, Vokes EE, Weichselbaum RR, Mell LK. Race and competing mortality in advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):40-4. PMID: 24134948.
      View in: PubMed
    29. Liu GF, Ranck MC, Solanki AA, Cao H, Kolokythas A, Wenig BL, Chen L, Ard S, Weichselbaum RR, Halpern H, Spiotto MT. Racial parities in outcomes after radiotherapy for head and neck cancer. Cancer. 2014 Jan 15; 120(2):244-52. PMID: 24122486.
      View in: PubMed
    30. Herman LC, Chen L, Garnett A, Feldman LE, Smith B, Weichselbaum RR, Spiotto MT. Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):52-8. PMID: 24055193.
      View in: PubMed
    31. Rudra S, Spiotto MT, Witt ME, Blair EA, Stenson K, Haraf DJ. Lymph node density--prognostic value in head and neck cancer. Head Neck. 2014 Feb; 36(2):266-72. PMID: 23765406.
      View in: PubMed
    32. Spiotto MT, Pytynia M, Liu GF, Ranck MC, Widau R. Animal models to study the mutational landscape for oral cavity and oropharyngeal cancers. J Oral Maxillofac Res. 2013 Apr 01; 4(1):e1. PMID: 24422024.
      View in: PubMed
    33. Schreiber K, Arina A, Engels B, Spiotto MT, Sidney J, Sette A, Karrison TG, Weichselbaum RR, Rowley DA, Schreiber H. Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res. 2012 May 01; 18(9):2526-33. PMID: 22415314.
      View in: PubMed
    34. Spiotto MT, Banh A, Papandreou I, Cao H, Galvez MG, Gurtner GC, Denko NC, Le QT, Koong AC. Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth. Cancer Res. 2010 Jan 01; 70(1):78-88. PMID: 20028872.
      View in: PubMed
    35. Fels DR, Ye J, Segan AT, Kridel SJ, Spiotto M, Olson M, Koong AC, Koumenis C. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res. 2008 Nov 15; 68(22):9323-30. PMID: 19010906.
      View in: PubMed
    36. King CR, Spiotto MT, Kapp DS. Obesity and risk of biochemical failure for patients receiving salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2009 Mar 15; 73(4):1017-22. PMID: 18707829.
      View in: PubMed
    37. King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):23-7. PMID: 18207668.
      View in: PubMed
    38. King CR, Presti JC, Brooks JD, Gill H, Spiotto MT. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2008 Apr 01; 70(5):1472-7. PMID: 17935902.
      View in: PubMed
    39. Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys. 2007 Sep 01; 69(1):54-61. PMID: 17459606.
      View in: PubMed
    40. Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley DA, Kranz DM, Schreiber H. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 2007 Jan 22; 204(1):49-55. PMID: 17210731.
      View in: PubMed
    41. Spiotto MT, Schreiber H. Floxed reporter genes: Flow-cytometric selection of clonable cells expressing high levels of a target gene after tamoxifen-regulated Cre-loxP recombination. J Immunol Methods. 2006 May 30; 312(1-2):201-8. PMID: 16674971.
      View in: PubMed
    42. Spiotto MT, Schreiber H. Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun. 2005 Jun 06; 5:8. PMID: 15934727.
      View in: PubMed
    43. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med. 2004 Mar; 10(3):294-8. PMID: 14981514.
      View in: PubMed
    44. Spiotto MT, Fu YX, Schreiber H. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr Opin Immunol. 2003 Dec; 15(6):725-30. PMID: 14630209.
      View in: PubMed
    45. Spiotto MT, Reth MA, Schreiber H. Genetic changes occurring in established tumors rapidly stimulate new antibody responses. Proc Natl Acad Sci U S A. 2003 Apr 29; 100(9):5425-30. PMID: 12702750.
      View in: PubMed
    46. Yu P, Spiotto MT, Lee Y, Schreiber H, Fu YX. Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med. 2003 Apr 21; 197(8):985-95. PMID: 12695490.
      View in: PubMed
    47. Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, Fu YX, Schreiber H. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 2002 Dec; 17(6):737-47. PMID: 12479820.
      View in: PubMed
    48. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells . Prostate. 2000 Feb 15; 42(3):186-95. PMID: 10639189.
      View in: PubMed
    49. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate. 2000 Feb 01; 42(2):88-98. PMID: 10617865.
      View in: PubMed
    50. Chung TD, Yu JJ, Kong TA, Spiotto MT, Lin JM. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate. 2000 Jan; 42(1):1-7. PMID: 10579793.
      View in: PubMed
    51. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate. 1999 Feb 15; 38(3):199-207. PMID: 10068344.
      View in: PubMed
    Spiotto's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _